Abstract:The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have marked a new phase of coronavirus disease 2019 (COVID-19). Understanding the recognition mechanisms of potent neutralizing monoclonal antibodies (NAbs) against the spike protein is pivotal for developing new vaccines and antibody drugs. Here, we isolated several monoclonal antibodies (MAbs) against the SARS-CoV-2 spike protein receptor-binding domain (S-RBD) from the B cell receptor repertoires of a SARS-CoV-2 convalescent. Among these MAbs, the antibody nCoV617 demonstrates the most potent neutralizing activity against authentic SARS-CoV-2 infection, as well as prophylactic and therapeutic efficacies against the human angiotensin-converting enzyme 2 (ACE2) transgenic mouse model in vivo . The crystal structure of S-RBD in complex with nCoV617 reveals that nCoV617 mainly binds to the back of the "ridge" of RBD and shares limited binding residues with ACE2. Under the background of the S-trimer model, it potentially binds to both "up" and "down" conformations of S-RBD. In vitro mutagenesis assays show that mutant residues found in the emerging new lineage B.1.1.7 of SARS-CoV-2 do not affect nCoV617 binding to the S-RBD. These results provide a new human-sourced neutralizing antibody against the S-RBD and assist vaccine development. IMPORTANCE COVID-19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic has posed a serious threat to global health and the economy, so it is necessary to find safe and effective antibody drugs and treatments. The receptor-binding domain (RBD) in the SARS-CoV-2 spike protein is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor. It contains a variety of dominant neutralizing epitopes and is an important antigen for the development of new coronavirus antibodies. The significance of our research lies in the determination of new epitopes, the discovery of antibodies against RBD, and the evaluation of the antibodies' neutralizing effect. The identified antibodies here may be drug candidates for the development of clinical interventions for SARS-CoV-2.

A Potent Neutralizing Human Antibody Reveals the N-terminal Domain of the Spike Protein of SARS-CoV-2 As a Site of Vulnerability

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Ultrapotent Bispecific Antibodies Neutralize Emerging SARS-CoV-2 Variants

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

A key linear epitope for a potent neutralizing antibody to SARS CoV 2 S RBD

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Defining the Features and Structure of Neutralizing Antibody Targeting the Silent Face of the SARS-CoV-2 Spike N-terminal Domain.

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

A Non-Ace2 Competing Human Single-Domain Antibody Confers Broad Neutralization Against SARS-CoV-2 and Circulating Variants.

Conserved Amino Acids W423 and N424 in Receptor-Binding Domain of SARS-CoV Are Potential Targets for Therapeutic Monoclonal Antibody.

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies